Skip to main content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: European Surgery 3/2017

01.06.2017 | original article

Fecal occult blood test/fecal carcinoembriogenic antigen dual rapid test as a useful tool for colorectal cancer screening

verfasst von: Maru Kim, Hyung-Jin Kim, In Kyu Lee, Seong-Taek Oh, Kyungja Han

Erschienen in: European Surgery | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Background

There are several screening tools for colorectal cancer (CRC). Most are limited in their application. The fecal occult blood test (FOBT) is a first-step screen for CRC that is limited by low sensitivity. This study aimed to prove the efficacy of combined FOBT and fecal carcinoembryogenic antigen (fCEA) as a CRC screening test.

Methods

Stool samples were collected preoperatively from 166 CRC patients expected to undergo elective surgery and from normal control patients. A fecal CEA/FOBT dual kit was created and the results from the use of this dual kit were compared against other clinicopathologic parameters.

Results

FOBT was positive in 103 of the 166 (62.0%) CRC patients and fCEA was positive in 114 (68.7%) patients, showing a statistically positive relationship. Among 63 FOBT negative patients, 29 (17%) cases were CEA positive. Thus, the CEA/FOBT dual test could detect CRC in 79.5% of the patients (132/166). The sensitivity and specificity of the dual FOBT/CEA test was 79.5% and 97.9%, respectively.

Conclusions

The FOBT/CEA dual test has increased sensitivity compared to the FOBT test and may have merit as a screening device for colorectal cancer. Population-based studies are required to confirm this potential.
Literatur
1.
Zurück zum Zitat Haug U, Knudsen AB, Brenner H, Kuntz KM. Is fecal occult blood testing more sensitive for left- versus right-sided colorectal neoplasia? A systematic literature review. Expert Rev Mol Diagn. 2011;11(6):605–16. CrossRefPubMed Haug U, Knudsen AB, Brenner H, Kuntz KM. Is fecal occult blood testing more sensitive for left- versus right-sided colorectal neoplasia? A systematic literature review. Expert Rev Mol Diagn. 2011;11(6):605–16. CrossRefPubMed
2.
Zurück zum Zitat Jung KW, Won YJ, Kong HJ, Oh CM, Shin A, Lee JS. Survival of Korean adult cancer patients by stage at diagnosis, 2006–2010: national cancer registry study. Cancer Res Treat. 2013;45(3):162–71. CrossRefPubMedPubMedCentral Jung KW, Won YJ, Kong HJ, Oh CM, Shin A, Lee JS. Survival of Korean adult cancer patients by stage at diagnosis, 2006–2010: national cancer registry study. Cancer Res Treat. 2013;45(3):162–71. CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Jung KW, Won YJ, Kong HJ, Oh CM, Seo HG, Lee JS. Prediction of cancer incidence and mortality in Korea, 2013. Cancer Res Treat. 2013;45(1):15–21. CrossRefPubMedPubMedCentral Jung KW, Won YJ, Kong HJ, Oh CM, Seo HG, Lee JS. Prediction of cancer incidence and mortality in Korea, 2013. Cancer Res Treat. 2013;45(1):15–21. CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Shin A, Choi KS, Jun JK, Noh DK, Suh M, Jung KW, et al. Validity of fecal occult blood test in the national cancer screening program, Korea. PLOS ONE. 2013;8(11):e79292. CrossRefPubMedPubMedCentral Shin A, Choi KS, Jun JK, Noh DK, Suh M, Jung KW, et al. Validity of fecal occult blood test in the national cancer screening program, Korea. PLOS ONE. 2013;8(11):e79292. CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Jin P, Wu ZT, Li SR, Li SJ, Wang JH, Wang ZH, et al. Colorectal cancer screening with fecal occult blood test: a 22-year cohort study. Oncol Lett. 2013;6(2):576–82. PubMedPubMedCentral Jin P, Wu ZT, Li SR, Li SJ, Wang JH, Wang ZH, et al. Colorectal cancer screening with fecal occult blood test: a 22-year cohort study. Oncol Lett. 2013;6(2):576–82. PubMedPubMedCentral
6.
7.
Zurück zum Zitat US Preventive Services Task Force Guides to Clinical Preventive Services. The guide to clinical preventive services 2012: recommendations of the US preventive services task force. Rockville: Agency for Healthcare Research and Quality; 2012. US Preventive Services Task Force Guides to Clinical Preventive Services. The guide to clinical preventive services 2012: recommendations of the US preventive services task force. Rockville: Agency for Healthcare Research and Quality; 2012.
8.
Zurück zum Zitat Kim Y, Lee S, Park S, Jeon H, Lee W, Kim JK, et al. Gastrointestinal tract cancer screening using fecal carcinoembryonic antigen. Ann Clin Lab Sci. 2003;33(1):32–8. PubMed Kim Y, Lee S, Park S, Jeon H, Lee W, Kim JK, et al. Gastrointestinal tract cancer screening using fecal carcinoembryonic antigen. Ann Clin Lab Sci. 2003;33(1):32–8. PubMed
10.
Zurück zum Zitat Hol L, van Leerdam ME, van Ballegooijen M, van Vuuren AJ, van Dekken H, Reijerink JC, et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut. 2010;59(1):62–8. CrossRefPubMed Hol L, van Leerdam ME, van Ballegooijen M, van Vuuren AJ, van Dekken H, Reijerink JC, et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut. 2010;59(1):62–8. CrossRefPubMed
12.
Zurück zum Zitat Sobhani I, Alzahouri K, Ghout I, Charles DJ, Durand-Zaleski I. Cost-effectiveness of mass screening for colorectal cancer: choice of fecal occult blood test and screening strategy. Dis Colon Rectum. 2011;54(7):876–86. CrossRefPubMed Sobhani I, Alzahouri K, Ghout I, Charles DJ, Durand-Zaleski I. Cost-effectiveness of mass screening for colorectal cancer: choice of fecal occult blood test and screening strategy. Dis Colon Rectum. 2011;54(7):876–86. CrossRefPubMed
13.
Zurück zum Zitat Hundt S, Haug U, Brenner H. Blood markers for early detection of colorectal cancer: a systematic review. Cancer Epidemiol Biomarkers Prev. 2007;16(10):1935–53. CrossRefPubMed Hundt S, Haug U, Brenner H. Blood markers for early detection of colorectal cancer: a systematic review. Cancer Epidemiol Biomarkers Prev. 2007;16(10):1935–53. CrossRefPubMed
14.
Zurück zum Zitat Wild N, Andres H, Rollinger W, Krause F, Dilba P, Tacke M, et al. A combination of serum markers for the early detection of colorectal cancer. Clin Cancer Res. 2010;16(24):6111–21. CrossRefPubMed Wild N, Andres H, Rollinger W, Krause F, Dilba P, Tacke M, et al. A combination of serum markers for the early detection of colorectal cancer. Clin Cancer Res. 2010;16(24):6111–21. CrossRefPubMed
15.
Zurück zum Zitat Kim YC, Kim JH, Cheung DY, Kim TH, Jun EJ, Oh JW, et al. The usefulness of a novel screening kit for colorectal cancer using the immunochromatographic fecal tumor M2 pyruvate kinase test. Gut Liver. 2015;9(5):641–8. PubMed Kim YC, Kim JH, Cheung DY, Kim TH, Jun EJ, Oh JW, et al. The usefulness of a novel screening kit for colorectal cancer using the immunochromatographic fecal tumor M2 pyruvate kinase test. Gut Liver. 2015;9(5):641–8. PubMed
16.
Zurück zum Zitat Tonus C, Sellinger M, Koss K, Neupert G. Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening: a meta-analysis. World J Gastroenterol. 2012;18(30):4004–11. CrossRefPubMedPubMedCentral Tonus C, Sellinger M, Koss K, Neupert G. Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening: a meta-analysis. World J Gastroenterol. 2012;18(30):4004–11. CrossRefPubMedPubMedCentral
Metadaten
Titel
Fecal occult blood test/fecal carcinoembriogenic antigen dual rapid test as a useful tool for colorectal cancer screening
verfasst von
Maru Kim
Hyung-Jin Kim
In Kyu Lee
Seong-Taek Oh
Kyungja Han
Publikationsdatum
01.06.2017
Verlag
Springer Vienna
Erschienen in
European Surgery / Ausgabe 3/2017
Print ISSN: 1682-8631
Elektronische ISSN: 1682-4016
DOI
https://doi.org/10.1007/s10353-017-0464-2

Weitere Artikel der Ausgabe 3/2017

European Surgery 3/2017 Zur Ausgabe